Spirobarbital
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
Synonyms | 5-spiro-(2'-ethyl-3'-5'-dimethyl-cyclopentyl)barbituric acid |
CAS Number | 12262-77-0 Y |
UNII | LR477QH2IL Y |
Chemical and physical data | |
Formula | C12H18N2O3 |
Molar mass | 238.282 g/mol |
3D model (Jmol) | Interactive image |
| |
(verify) |
Spirobarbital is a barbiturate derivative developed by Eli Lilly in the 1940s.[1] It has hypnotic and sedative effects, and has a moderate potential for abuse.[2]
References
- ↑ US Patent 2561688
- ↑ Isbell H, Chrusciel TS. Dependence Liability of Non-Narcotic Drugs. Bulletin of the World Health Organisation 1970; 43: Supplement.
Alcohols | |
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids | |
Imidazoles | |
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines |
|
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: GABAergics |
This article is issued from Wikipedia - version of the 11/11/2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.